Key words: Anticonvulsants; Drug hypersensitivity syndrome; Pseudolymphoma; Eosinophilia Abstract Immune-mediated drug reactions are a potentially life-threatening complication of antiseizure medications. Drug hypersensitivity syndrome (DHS) is the best recognised of these, presenting with fever, eosinophilia, rash and internal organ involvement. Isolated lymphadenopahy is a less recognised immune-mediated reaction to antiseizure drugs such as lamotrigine. We describe the case of a 24 year-old woman who developed lamotriginerelated bilateral cervical lymphadenopathy (pseudolymphoma) fifteen months following therapy initiation. This is the second such case reported in the medical literature.
Introduction
Lamotrigine a triazine-derived antiseizure drug which acts to stabilise neuronal membranes through inhibition of voltage-sensitive sodium and calcium channel opening. Drug reactions are an important consideration when prescribing this medication. Skin rashes are a worrying side-effect, as they may signal the development of Stevens-Johnson syndrome, toxic epidermal necrolysis or drug hypersensitivity syndrome (DHS). A less common, and less recognised reaction to lamotrigine is the development of localised lymphadenopathy (pseudolymphoma) without systemic features or rash. In contrast to DHS and severe cutaneous adverse reactions, which happen within weeks of therapy initiation, druginduced pseudolymphoma often occurs months down the line. In patients taking lamotrigine and other antiseizure drugs, clinicians should consider drug reactions in the differential diagnosis of isolated lymphadenopathy, especially in the setting of peripheral blood eosinophilia. Fifteen months after initiation of lamotrigine, she complained of cough productive of yellow sputum. She was afebrile. Chest examination was normal. Lymphadenopathy was detected in the right cervical chain. Other lymph node basins, tonsillar tissue and spleen were of normal size. Spirometry was within normal limits. High resolution CT chest and neck showed extensive bilateral cervical lymphadenopathy and patchy ground-glass nodules in multiple lobes but no intra-thoracic adenopathy. Full blood count, serum chemistries, as well as testing for rheumatoid factor, anti-citric citrullinated peptide antibodies, antinuclear antibodies, human immunodeficiency virus, Epstein-Barr virus, cytomegalovirus, toxoplasma and tuberculosis was all normal or negative. Erythrocyte sedimentation rate and c-reactive protein were elevated at 95mm/h (normal<23mm/h) and 16mg/L (normal<5mg/L) respectively. Histology of an excisional lymph node biopsy showed reactive follicular hyperplasia with capsular thickening without malignancy or granuloma. A review of prior blood testing revealed intermittent low-grade eosinophilia since introduction of lamotrigine (see Table 1 ). A diagnosis of lamotrigine-related pseudolymphoma was made. Lamotrigine was gradually withdrawn and her lymphadenopathy and pulmonary findings (which also likely represented a medication toxicity) have resolved.
Case report

Discussion
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
Lamotrigine is an antiseizure drug which acts through voltage-sensitive sodium and calcium channels to reduce the release of excitatory neurotransmitters. Cutaneous adverse reactions are the most feared complication of therapy, because the presence of a rash can herald the development of devastating complications such as Stevens-Johnson syndrome, toxic-epidermal necrolysis or a drug-hypersensitivity syndrome (DHS). Localised lymphadenopathy without systemic symptoms (pseudolymphoma) is a much less appreciated complication of therapy.
Both drug-induced pseudolymphoma and DHS represent immune reactions to medications, but differ greatly in their time-course, clinical manifestations and treatment [1] . The most commonly implicated medications are antiseizure drugs such as phenytoin, carbamazepine and lamotrigine, but also allopurinol, atidepressants and some antihypertensive medications [2] .
Pseudolymphoma may present with isolated lymphadenopathy, cutaneous lesions or both [1, 3] . The presence of systemic features and internal organ dysfunction is unusual and onset is generally weeks to months following therapy initiation [1, 3] . Localised lymphadenopathy secondary to lamotrigine has been reported once previously [3] . In this case, as in ours, the cervical nodes were involved. The pathogenesis of this reactive 'pseudolymphoma', which can be B-cell, T-cell or mixed-type is incompletely understood. As in this case, medication withdrawal is generally all that is necessary to treat the condition [1, 3] .
In contrast, DHS (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]), a well-recognised complication of antiseizure drug treatment, is characterised by a maculopapular rash, fever, leucocytosis and internal organ involvement [4] . Onset is more acute than pseudolymphoma, beginning in the first few weeks following therapy initiation. Treatment with immunosuppressive drugs, intravenous immunoglobulin and/or plasma exchange is often necessary, especially in severe cases.
Clinicians should consider drug reactions when assessing patients with localised lymphadenopathy. Drug initiation may have taken place weeks to month prior to the onset of symptoms. In our case, lamotrigine was likely the offending medication, though in both reported cases of lamotrigine-related pseudolymphoma (ours and one other previous case), patients were concurrently taking carbamazepine, a medication whose effective plasma concentration may be increased by lamotrigine [3, 5] . Intermittent or low-grade eosinophilia may be a clue to the diagnosis. Discontinuation of the offending drug (e.g. lamotrigine) in these cases often leads to resolution of clinical symptoms.
Highlights
 Localised lymphadenopathy, especially cervical, is a potential complication of antiseizure therapy  Drug-induced pseudolymphoma is a distinct entity from, and occurs without other features of drug hypersensitivity syndrome (fever, rash, internal organ involvement)  Low-grade or intermittent eosinophilia in a patient with lymphadenopathy should prompt the clinician to consider a diagnosis of a drug reaction
